Loading...
Ranolazine remains a modestly popular anti-anginal drug. These researchers performed a prespecified substudy of its effect in diabetes patients enrolled in the multicenter, placebo-controlled RIVER-PCI trial of 2651 patients with chronic angina and incomplete revascularization after percutaneous coronary intervention (NEJM JW Cardiol Feb 2016 and Lancet 2016; 387:136). In RIVER-PCI, no difference was seen in the primary endpoint (first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization) at a median follow-up of 643 days.
In this substudy examining 961 patients with diabetes, angina frequency at 12 months did not differ between ranolazine and placebo (least squares mean difference: 1.7…